third quarter consolidated revenue of $num-one billion represents num-two% reported revenue growth versus the third quarter of year-five and reflects a $num-three million tailwind from foreign exchange.
qtr-three adjusted earnings per share of $num-one grew num-two% versus year-five and num-three% versus year-four, reaching the high end of our third quarter guidance range of $num-four to $num-one.
spend controls and a favorable tax rate drove qtr-three adjusted earnings per share of $num-one, representing num-two% growth versus year-five, num-three% growth versus year-four and achieving the high end of our guidance range of $num-four to $num-one.
moving to below the line.
third quarter consolidated revenue of $num-one billion represents num-two% reported revenue growth versus the third quarter of year-five and reflects a $num-three million tailwind from foreign exchange. for the organic comparison to year-four, full year year-four sales exclude $num-four million in sales of our embolic beads portfolio and intrauterine health franchise as well as $num-five million in specialty pharmaceutical sales and at the midpoint of guidance, year-six sales exclude approximately $num-six million in sales from recent acquisitions, including [technical issues] btg interventional medicines through mid-august, preventice, farapulse and lumenis as well as $num-seven million of specialty pharmaceutical sales prior to divestiture.
third quarter consolidated revenue of $num-one billion represents num-two% reported revenue growth versus the third quarter of year-five and reflects a $num-three million tailwind from foreign exchange. for the organic comparison to year-four, full year year-four sales exclude $num-four million in sales of our embolic beads portfolio and intrauterine health franchise as well as $num-five million in specialty pharmaceutical sales and at the midpoint of guidance, year-six sales exclude approximately $num-six million in sales from recent acquisitions, including [technical issues] btg interventional medicines through mid-august, preventice, farapulse and lumenis as well as $num-seven million of specialty pharmaceutical sales prior to divestiture.
our fourth quarter adjusted earnings per share estimate is $num-one to $num-two, and we're updating full year adjusted earnings per share to a revised range of $num-three to $num-four.
for the fourth quarter, adjusted earnings per share is expected to be in a range of $num-one to $num-two.